Cadrenal Therapeutics (CVKD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CVKD Stock Forecast

Cadrenal Therapeutics stock forecast is as follows: an average price target of $32.00 (represents a 96.08% upside from CVKD’s last price of $16.32) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CVKD Price Target

The average price target for Cadrenal Therapeutics (CVKD) is $32.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $32.00. This represents a potential 96.08% upside from CVKD's last price of $16.32.

CVKD Analyst Ratings

Buy

According to 1 Wall Street analysts, Cadrenal Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CVKD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cadrenal Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Joseph Pantginis	H.C. Wainwright	$32.00	$14.93	114.33%	96.08%

Row per page

Go to

The latest Cadrenal Therapeutics stock forecast, released on Nov 11, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $32.00, which represents a 114.33% increase from the stock price at the time of the forecast ($14.93), and a 96.08% increase from CVKD last price ($16.32).

Cadrenal Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	1
Avg Price Target	$32.00	$32.00	$32.00
Last Closing Price	$16.32	$16.32	$16.32
Upside/Downside	96.08%	96.08%	96.08%

In the current month, the average price target of Cadrenal Therapeutics stock is $32.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 96.08% increase as opposed to Cadrenal Therapeutics's last price of $16.32. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 11, 2024	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

Cadrenal Therapeutics's last stock rating was published by H.C. Wainwright on Nov 11, 2024. The company gave CVKD a "Buy" rating, the same as its previous rate.

Cadrenal Therapeutics Financial Forecast

Cadrenal Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Cadrenal Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CVKD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Cadrenal Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict CVKD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cadrenal Therapeutics's previous annual EBITDA (undefined) of $NaN.

Cadrenal Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-1.57M	$-1.53M	$-1.39M	$-2.37M	$-2.51M	$-2.41M	$-1.36M
High Forecast	$-1.57M	$-1.53M	$-1.39M	$-2.37M	$-2.17M	$-2.41M	$-1.36M
Low Forecast	$-1.57M	$-1.53M	$-1.39M	$-2.37M	$-2.78M	$-2.41M	$-1.36M
Surprise %	-	-	-	-	-	-	-

Cadrenal Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CVKD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cadrenal Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Cadrenal Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CVKD last annual SG&A of $NaN (undefined).

Cadrenal Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-1.42	$-1.39	$-1.26	$-2.15	$-2.28	$-2.18	$-1.27
High Forecast	$-1.42	$-1.39	$-1.26	$-2.15	$-1.96	$-2.18	$-1.27
Low Forecast	$-1.42	$-1.39	$-1.26	$-2.15	$-2.52	$-2.18	$-1.27
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Cadrenal Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CVKD previous annual EPS of $NaN (undefined).

Cadrenal Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PMVP	PMV Pharmaceuticals	$1.56	$18.00	1053.85%	Buy
ANTX	AN2 Therapeutics	$1.00	$8.75	775.00%	Buy
ANEB	Anebulo Pharmaceuticals	$1.53	$6.00	292.16%	Buy
IKT	Inhibikase Therapeutics	$1.97	$6.50	229.95%	Buy
XCUR	Exicure	$3.94	$12.00	204.57%	-
GPCR	Structure Therapeutics	$31.75	$92.40	191.02%	Buy
MLYS	Mineralys Therapeutics	$11.40	$30.00	163.16%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
FHTX	Foghorn Therapeutics	$7.71	$16.33	111.80%	Buy
CVKD	Cadrenal Therapeutics	$16.32	$32.00	96.08%	Buy
SABS	SAB Biotherapeutics	$3.21	$5.67	76.64%	Buy
CNTA	Centessa Pharmaceuticals	$16.10	$23.25	44.41%	Buy
MNPR	Monopar Therapeutics	$18.45	$22.00	19.24%	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy

CVKD Forecast FAQ

Is Cadrenal Therapeutics a good buy?

Yes, according to 1 Wall Street analysts, Cadrenal Therapeutics (CVKD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CVKD's total ratings.

What is CVKD's price target?

Cadrenal Therapeutics (CVKD) average price target is $32 with a range of $32 to $32, implying a 96.08% from its last price of $16.32. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cadrenal Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CVKD stock, the company can go up by 96.08% (from the last price of $16.32 to the average price target of $32), up by 96.08% based on the highest stock price target, and up by 96.08% based on the lowest stock price target.

Can Cadrenal Therapeutics stock reach $20?

CVKD's average twelve months analyst stock price target of $32 supports the claim that Cadrenal Therapeutics can reach $20 in the near future.

What is Cadrenal Therapeutics's current price target trend?

1 Wall Street analyst forecast a $32 price target for Cadrenal Therapeutics (CVKD) this month, up 96.08% from its last price of $16.32. Compared to the last 3 and 12 months, the average price target increased by 96.08% and increased by 96.08%, respectively.